NACLC 2025

December 05-07, 2025
Chicago, IL, USA

2025 North America Conference on Lung Cancer

Explore more Oncology congress materials

Results(3)

Oncology

Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer: Updates From Jazz EMERGE 402

Author(s): Firas Badin, Philip Lammers, Geoffrey Li et al.

Safety and Preliminary Efficacy of Zanidatamab in Patients With HER2-Overexpressing Non-Small Cell Lung Cancer: Subgroup Analysis From a Phase 1 Study

Author(s): Do-Youn Oh, Tae Min Kim, Theresa Samuel Nached et al.

Patient-reported outcomes (PROs) from IMforte: A Phase 3 study of first-line maintenance treatment with lurbinectedin + atezolizumab versus atezolizumab in patients with extensive-stage small cell lung cancer (ES-SCLC)

Author(s): Roy S. Herbst, Luis Paz-Ares, Hossein Borghaei et al.

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.